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Purpose: The aim of this study was to report the outcome of primary or metastatic lung cancer patients
undergoing volumetric modulated arc therapy for stereotactic body radiation therapy (VMAT-SBRT).
Methods and materials: From October 2010 to December 2013, consecutive 67 lung cancer patients received
single-arc VMAT-SBRT using an Elekta-synergy system. All patients were treated with an abdominal compressor.
The gross tumor volumes were contoured on 10 respiratory phases computed tomography (CT) datasets from
4-dimensional (4D) CT and merged into internal target volumes (ITVs). The planning target volume (PTV) margin
was isotropically taken as 5 mm. Treatment was performed with a D95 prescription of 50 Gy (43 cases) or 55 Gy
(12 cases) in 4 fractions for peripheral tumor or 56 Gy in 7 fractions (12 cases) for central tumor.
Results: Among the 67 patients, the median age was 73 years (range, 59–95 years). Of the patients, male was 72%
and female 28%. The median Karnofsky performance status was 90-100% in 39 cases (58%) and 80-90% in 20 cases
(30%). The median follow-up was 267 days (range, 40–1162 days). Tissue diagnosis was performed in 41 patients
(61%). There were T1 primary lung tumor in 42 patients (T1a in 28 patients, T1b in 14 patients), T2 in 6 patients,
three T3 in 3 patients, and metastatic lung tumor in 16 patients. The median mean lung dose was 6.87 Gy (range,
2.5-15 Gy). Six patients (9%) developed radiation pneumonitis required by steroid administration. Actuarial local
control rate were 100% and 100% at 1 year, 92% and 75% at 2 years, and 92% and 75% at 3 years in primary and
metastatic lung cancer, respectively (p = 0.59). Overall survival rate was 83% and 84% at 1 year, 76% and 53% at
2 years, and 46% and 20% at 3 years in primary and metastatic lung cancer, respectively (p = 0.12).
Conclusions: Use of VMAT-based delivery of SBRT in primary in metastatic lung tumors demonstrates high local
control rates and low risk of normal tissue complications.
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Stereotactic body radiation therapy (SBRT) is emerging
as an effective treatment for patients with medically in-
operable, early stage lung cancers as evidenced by local
control rates reaching 90% at three years with relatively
minimal toxicity [1,2].
The report from Mayo Clinic to validate the use of
SBRT of 50 Gy in 5 fractions using IMRT 7 non-coplanar
beams for 26 patients with medically inoperable Stage I* Correspondence: yamachan07291973@yahoo.co.jp
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article, unless otherwise stated.lung cancer was published [3]. Use of IMRT during SBRT
has not been without issues for some authors, with ques-
tions on the feasibility of IMRT delivery within small fields
typical of SBRT [4], and concerns that organ motion could
negate the benefits of the IMRT [5]. Recently, it was re-
ported that volumetric modulated arc therapy (VMAT),
which is a novel rotational technique and an extension of
intensity modulated radiation therapy (IMRT), is applic-
able for SBRT for lung tumors [6-8]. This technique
achieves treatment plan qualities comparable to the non-
coplanar IMRT technique and dramatically decreases the
total treatment time for each fraction [9].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Patient and tumor characteristics
Factors No. Rate
Age
Range 56-95 years old




























Left upper 18 27%
Left lower 10 15%
Right upper 17 25%
Right middle 9 13%






Before SBRT 5 7%
After SBRT 3 4%
None 57 85%
Yamashita et al. Radiation Oncology 2014, 9:243 Page 2 of 6
http://www.ro-journal.com/content/9/1/243To date, there are no published clinical studies specially
addressing VMAT during SBRT for lung cancer. The pur-
pose of the present report is therefore to provide clinical
results for a group of primary or metastatic lung cancer
patients whom we have treated with a VMAT-SBRT ap-
proach. This study has been done retrospectively and was
proven by a local ethic/IRB board (No. 3372).
Materials and methods
Tumor biopsy was attempted in all patients to confirm
malignancy unless medically or surgically contraindi-
cated. Before initiation of treatment, patients were ex-
pected to undergo complete history taking and physical
examination, contrast-enhanced computed tomography
(CT) imaging of the chest, [18 F] fluorodeoxyglucose
positron emission tomography (FDG-PET) scanning for
staging, pulmonary function testing (PFTs) including
forced expiratory volume at 1 s (FEV1.0), and diffusion
capacity to carbon monoxide (DLCO) only before SBRT
and brain imaging (contrast-enhanced CT or magnetic
resonance imaging [MRI]). The PFT was not performed
routinely after SBRT.
Patient and tumor characteristics
From October 2010 to December 2013, consecutive 67
lung cancer patients received single-arc VMAT-SBRT
using an Elekta-synergy system. Complete data were ac-
quired and evaluated for all 67 patients. Patient and
tumor characteristics are summarized in Table 1. Among
the 67 patients, the median age was 73 years (range, 59–
95 years). Of the patients, male was 72% and female
28%. The median Karnofsky performance status was 90-
100% in 39 cases (58%) and 80-90% in 20 cases (30%).
Tissue diagnosis was performed in 41 patients (61%).
There were T1 primary lung tumor in 42 patients (T1a
in 28 patients, T1b in 14 patients), T2 in 6 patients,
three T3 in 3 patients, and metastatic lung tumor in 16
patients. In our institution, some T3 tumors only with
direct invasion to chest wall, without lymph node metas-
tasis, and without the indication of radical surgery were
treated with SBRT-alone. As to histology, squamous cell
carcinoma was diagnosed in 26 cases, adenocarcinoma
in 10 cases, small cell carcinoma in 2 cases, and non-
small cell carcinoma, carcinoma, and undifferentiated
carcinoma in one case, respectively.
39% of the patients were treated without histology. In
primary cases without histology, PET/CT scan was com-
pulsory. Either the SUV-max value over 3.0 by PET scan
or the obvious tendency for increased tumor size by CT
scans in the absence of significant up-take increase of
FDG was necessary conditions for SBRT. Such cases had
been discussed in weekly interdisciplinary cancer board
and treatment decisions were based on recommenda-
tions of such a cancer board.Selection of these patients for SBRT was not limited
by baseline performance, pulmonary status, or tumor lo-
cation. Patients were followed-up initially 6 to 8 weeks
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contrast-enhanced CT imaging of the chest. Thereafter,
routine follow-up was every 3 months for 2 years, with
CT imaging at each visit and PFTs twice yearly. Tumor
responses were classified into complete response, partial
response, stable disease, and progression based on Re-
sponse Evaluation Criteria in Solid Tumors (RECIST).
Toxicity was assessed retrospectively from patient clin-
ical data using the Common Terminology Criteria for
Adverse Events version 4.0 (CTCAE).
All patients underwent computed tomography (CT)-
based SBRT planning for IMRT. Four-dimensional CT
images for treatment planning were acquired with 2-
mm-thick slices using an Aquilion LB model scanner
(16-slice; Toshiba). The patients were in the supine pos-
ition and fitted with an abdominal compressor [10,11].
The Elekta stereotactic body frame (SBF) was also used
to minimize breathing artifacts for treatment planning
CT. Scans were performed using the AZ-733 V system
(Anzai Medical) as an external respiratory monitoring
system. Each respiratory phase scan was transferred to a
Pinnacle3, version 9.0, system (Philips).
The gross tumor volume (GTV) was delineated using
the lung window (window, 1600 HU; level, −300 HU),
on the 10 respiratory phase CT datasets from 4D CT re-
spiratory sorting. Then, the ITV was produced using an
integration of the GTVs as defined in these 10 phases. In
all cases, the PTV was defined by adding a uniform 5-
mm margin to the ITV to compensate for setup errors.
Critical structures including but not limited to ipsilateral
and contralateral lungs, spinal cord, and esophagus were
outlined. PET-CT data were not used directly for image-
guided planning.
Patients received a D95 prescription of 50 Gy (43 cases)
before August 2013 or 55 Gy (12 cases) after August 2013
in 4 fractions for peripheral tumor or 56 Gy in 7 fractions
(12 cases) for central tumor as defined by RTOG 0236
[12]. The single-arc VMAT-SBRT with 6 MV was created
by SmartArc (Pinnacle3; Philips). Dose constraints for nor-
mal organs at risk for complications were the ipsilateral
lung volume receiving 20 Gy (V20) <10% and 5 Gy <25%
contralateral lung volume receiving 20 Gy (V20) <0% and
5 Gy <15%; spinal cord volumes receiving 15 Gy (V15) <0%;
heart volumes receiving 30 Gy <0%; liver volume receiving
30 Gy <0%; body receiving 50 Gy <0%. Dosimetric planning
and plan analysis were performed in Pinnacle3. The
collapsed cone convolution method (which was com-
parable to superposition method) in Pinnacle3 was used
as the heterogeneous correction method for the lungs. All
final calculations were performed with a grid size of
2.0 mm. Dose distributions were calculated using peak
exhalation CT data.
In primary cases, SBRT was the only treatment modality
and no additional chemotherapy treatment was performedduring disease control. In metastatic cases, no patients
had received lung irradiation before SBRT.
Recently, a system for performing pre-treatment
respiration-correlated CBCT, namely 4D CBCT, was
developed by using an image-based recognition tech-
nique of the respiration phase [9,13]. Registration
was semi-automatically performed using such pre-4D
CBCT.Image guided RT procedure
VMAT-SBRT was performed using a photon beam pro-
vided by a Synergy linear accelerator (Elekta) equipped
with the kV CBCT system that included a kV x-ray tube
and flat-panel detector mounted on each side of the gan-
try, perpendicular to the treatment beam. In advance,
the isocenter information of the treatment plan, regions
of interest, and CT image set for peak exhalation were
sent to the workstation with application software loaded
onto the x-ray volume imaging functionality PC (XVI
system, version 4.2). As an image guided RT (IGRT) pro-
cedure, pre-4D CBCT images were acquired with kV im-
aging parameters of a beam of 120 kVp and 20 mA/
20 ms at an axial field length of 20 cm with a bow-tie
filter immediately before daily treatment. In this case,
the typical number of frames was approximately 650 in
a pre-CBCT scan. Tumor registration was performed
between obtaining a planning CT image for peak exhal-
ation and obtaining the aforementioned 4D CBCT
image. In the registration procedure, the chamfer match-
ing (bone matching) was used first, and then, the manual
registration was performed using ITV and PTV. There-
after, the patient couch was adjusted according to the
registration result.Statistical analysis
The outcomes of interest were local control and sur-
vival, measured from the time of the first day of SBRT
until death or last patient contact. Local failure was
defined as progressive and increasing CT scan abnor-
malities confirmed by progressive and incremental in-
creases in the standardized uptake values (SUVs) of a
lesion on serial PET imaging, with or without biopsy
[14]. The survival probability was illustrated using
Kaplan-Meier curves, and the log-rank test was used
to determine whether a statistically significant difference
was present among patient groups. The correlation coeffi-
cient was calculated between the occurrence of radiation
pneumonitis required by steroid administration and the
value of FEV1.0 or DLCO. The statistical analyses were
performed using StatView 5.0 (SAS Institute, Cary, NC),
and a value of p <0.05 was considered statistically
significant.
Figure 2 Overall survival curves by primary and metastatic
lung cancer.
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Results of SBRT planning
The median total treatment period was 6 days (range, 4–13
days). The ITV ranged from 1.6 to 80.1 cc (median, 5.8 cc).
The median maximum, minimum, and mean dose within
PTV was 58 Gy (range, 52.7-77 Gy), 48 Gy (range, 10.6-
60.7 Gy), and 53.9 Gy (50.6-68 Gy). The median mean lung
dose was 6.87 Gy (range, 2.5-15 Gy). The median lung V20,
V15, and V5 were 9% (range, 3-21%), 12% (range, 5–30%),
and 25% (9-60%), respectively.
Clinical results
The median follow-up was 8.9 months (range, 1.3-
38.7 months). Limiting to surviving cases, the minimum
follow-up time was 10.1 months. At the time of analysis,
48 cases were alive and 17 cases were dead. Actuarial
local control rate were 100% and 100% at 1 year, 92%
and 75% at 2 years, and 92% and 75% at 3 years in pri-
mary and metastatic lung cancer, respectively (p = 0.59)
(Figure 1). Overall survival rate was 83% and 84% at
1 year, 76% and 53% at 2 years, and 46% and 20% at
3 years in primary and metastatic lung cancer, respect-
ively (p = 0.12) (Figure 2). Actuarial disease control rate
was 86% and 66% at 1 year, 78% and 41% at 2 years, and
78% and 41% at 3 years in primary and metastatic lung
cancer, respectively (p = 0.013) (Figure 3).
For the dead patients of primary 10 cases and meta-
static 7 cases, the cause of death was other metastases
but lung in 11 cases, local problems in one case, and
other disease in 5 cases. All three cases with primary T3
tumor were dead of distant metastases. For living 7 cases
with disease (primary 4 cases and metastatic 3 cases),
the pattern of relapse was all distant metastases.
Toxicity
According to Common Terminology Criteria for Adverse
Events (CTCAE) v4.0, grade 2 skin reactions were seen inFigure 1 Local control curves by primary and metastatic
lung cancer.3 cases (grade 3 or more in zero) and grade 2 or more fa-
tigue and chest wall pain requiring pain medication was
never seen. Six patients (9%) developed radiation pneu-
monitis required by steroid administration. There was no
correlation between the occurrence of radiation pneumon-
itis required by steroid administration and the value of
FEV1.0 or DLCO. No other toxicities not lower than grade
3 were seen. No rib fractures or late esophageal toxicities
were seen.
Discussion
To our knowledge, this is the first report discussing the
clinical result of IMRT SBRT using VMAT. One poten-
tial problem when inverse planning for lung cancer
treatment is that the optimization of beam fluence only
takes into account a single three-dimensional volumetric
data set. For this, the actual VMAT that continuously
delivers the dose in all respiratory phases may yield a
dose distribution that differs from the plan. In order to
compensate for this fact, the target volume can beFigure 3 Disease control curves by primary and metastatic
lung cancer.
Yamashita et al. Radiation Oncology 2014, 9:243 Page 5 of 6
http://www.ro-journal.com/content/9/1/243extended to encompass the range of target motion by
using 4D-CT scan, and field shapes can be defined as
the target surroundings. Alternatively, the inverse plan
that constrains MLC motion in VMAT forms field
shapes that do not hide the target in lung cancer treat-
ment. In this case, the beam intensity is mainly modu-
lated by changing gantry speed and dose rate. Recently,
it was reported that VMAT, which is a novel rotational
technique and an extension of IMRT, is applicable for
SBRT for lung tumors [7,15]. This technique achieves
treatment plan qualities comparable to the non-coplanar
IMRT technique and dramatically decreases the total
treatment time for each fraction. VMAT drastically re-
duced the amount of radiation intensity, known as the
monitor unit (MU). Thus, VMAT was found to be able
to deliver the desired dose distribution in a shorter time
than IMRT. Nowadays, VMAT plays a main role in
high-precision radiotherapy treatment.
The study by Crabtree et al. [16] compared prospect-
ive clinical trials of SBRT, sub-lobular resection, and ra-
diofrequency ablation of three clinical trials and they
concluded that, among appropriately matched patients,
no difference was seen in early morbidity between sub-
lobar resection and SBRT. Both articles by Andratschke
et al. [17] and by Guckenberger et al. [18] presented
data of a large number of patients with inoperable stage
I non-small cell lung cancer concerning safety of treat-
ment and patterns of failure. Andratschke et al. [17] re-
ported that all 10 local failures were observed in patients
with T2 tumors (n = 61), isolated regional recurrence
was observed in 7.6% (n = 6), and the crude rate of dis-
tant progression was 20.7% (n = 22) and that no grade
3–5 acute toxicity was observed. Guckenberger et al.
[18] reported that 3-year freedom from local progression
was 79.6% and that radiation-induced pneumonitis grade
2 or higher was observed in 38 of 512 patients (7.4%)
and grade 5 was documented in two patients (0.4%).
The present clinical results support VMAT-based
IMRT-SBRT delivery for lung tumors. There have been
previous nonclinical studies validating the appropriate-
ness of IMRT in the setting of radiosurgery or SBRT.
Benedict et al. [19] carried out a planning study on four
brain small lesion cases to assess the potential for im-
proved tumor coverage and normal tissue sparing using
intensity-modulated stereotactic radiosurgery. These in-
vestigators demonstrated significant dosimetric improve-
ments for the small, irregularly shaped lesions compared
with the results of other techniques, with reductions in
critical organ irradiation. Cardinale et al. [20] reported
similar results favoring IMRT in their report on three
SBRT techniques, namely, arcs, non-coplanar fixed fields,
and IMRT. In an analysis of organ motion effects on
IMRT treatments with segments of few monitor units.
Seco et al. [21] concluded that for most clinical cases, anynon-negligible effects of IMRT dose delivery may be clin-
ically irrelevant when multiple beams are used. On the
other hand, Dvorak et al. [22] studied the impact of IMRT
and leaf width on SBRT for liver and lung lesions. They
compared plans generated for 10 patients treated with
multi-leaf collimator (MLC)–based conformal therapy to
seven alternative plans including one for micro-MLC
IMRT treatment as in the BrainLAB system. They found
that no significant differences could be observed in terms
of target conformity between standard and IMRT dose
distributions. Videtic et al. [3] studied the use of SBRT of
50 Gy in 5 fractions using IMRT seven non-coplanar
beams using a Novalis/BrainLAB system for medically in-
operable 28 Stage I lung cancers of 26 patients. They re-
ported that the 3-year local control for T1 (22 lesions) and
T2 lesions (6 lesions) was 93.1% and 100%, respectively.
Hodge et al. [23] reported that delivery of IG-SBRT via
helical tomotherapy using extreme hypofractionation in
patients with early stage medically inoperable non-small
cell lung cancer is feasible and well tolerated.
The limitations of this study include its retrospective
nature. Although the small sample size also represents a
limitation of this study, the median follow-up of close to
8.9 months, along with the meticulous documentation of
patient status, lend support to the conclusions drawn
from this cohort. Although this is a general limitation of
lung cancer in following up with CT, it was the difficulty
to discriminate between lung tissue changes after SBRT
(i.e. post-RT scars) and true recurrences (i.e. progress) in
this study, too.
Conclusion
Use of VMAT-based delivery of SBRT in primary in
metastatic lung tumors demonstrates high local control
rates and low risk of normal tissue complications.
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